Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, USA, and Munich, Germany. Working with leading geneticists and valued partners like Origenis, Neuron23 leverages genetic breakthroughs and artificial intelligence technology to discover promising approaches and develop new drugs more efficiently than ever before.

Our pipeline focuses on creating the right medicines for the right patients suffering from genetic disorders in disciplines ranging from neurodegenerative diseases to immune disorders. Right now, Neuron23 has a pipeline of preclinical, small molecule candidates, licensed as part of a drug discovery partnership with Origenis. Our lead candidate targets LRRK2 as a potential treatment for Parkinson’s Disease.

Company Information

January 31, 2022